Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -30.12% is 35% below its 5-year average of -22.26%, near the low end of its 5-year range (-30.12%–-10.31%).
As of the fiscal period ended Tuesday, June 30, 2026. 3.50% below its 12-month average of -29.10%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -30.12%.
RETURN ON EQUITY (ROE)
-30.12%
RETURN ON EQUITY (ROE) AVG TTM
-29.10%
RETURN ON EQUITY (ROE) AVG 3Y
-25.72%
RETURN ON EQUITY (ROE) AVG 5Y
-22.26%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-3.50%
CURRENT VS 3Y AVG
-17.09%
CURRENT VS 5Y AVG
-35.31%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.10%
median of 707 covered companies
CURRENT VS SECTOR MEDIAN
+26.73%
vs the sector median at left
Seer, Inc.
Market Cap
$121.23M
Return on Equity (ROE)
-30.12%
TTM Avg
-29.10%
3Y Avg
-25.72%
5Y Avg
-22.26%
Market Cap
$121.02M
Return on Equity (ROE)
-148.56%
TTM Avg
-96.59%
3Y Avg
-83.25%
5Y Avg
-64.44%
Market Cap
$120.58M
Return on Equity (ROE)
-2.13%
TTM Avg
-45.09%
3Y Avg
-61.80%
5Y Avg
-44.27%
Market Cap
$122.27M
Return on Equity (ROE)
-165.57%
TTM Avg
-146.09%
3Y Avg
30.63%
5Y Avg
465.14%
Market Cap
$121.37M
Return on Equity (ROE)
-663.38%
TTM Avg
-427.48%
3Y Avg
-294.92%
5Y Avg
-251.31%
Market Cap
$120.19M
Return on Equity (ROE)
-61.33%
TTM Avg
-137.84%
3Y Avg
-101.43%
5Y Avg
-77.25%
Market Cap
$116.00M
Return on Equity (ROE)
-0.05%
TTM Avg
-43.47%
3Y Avg
9.13%
5Y Avg
-18.50%
Market Cap
$125.56M
Return on Equity (ROE)
N/A
TTM Avg
143.89%
3Y Avg
2.05%
5Y Avg
-53.47%
Market Cap
$125.77M
Return on Equity (ROE)
-71.83%
TTM Avg
-71.89%
3Y Avg
-76.88%
5Y Avg
-67.88%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seer, Inc. (SEER) | $121.23M | -30.12% | -29.10% | -25.72% | -22.26% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $121.02M | -148.56% | -96.59% | -83.25% | -64.44% |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | -2.13% | -45.09% | -61.80% | -44.27% |
| TuHURA Biosciences, Inc. (HURA)vs › | $122.27M | -165.57% | -146.09% | 30.63% | 465.14% |
| Cibus, Inc. (CBUS)vs › | $121.37M | -663.38% | -427.48% | -294.92% | -251.31% |
| Spruce Biosciences, Inc. (SPRB)vs › | $120.19M | -61.33% | -137.84% | -101.43% | -77.25% |
| Coya Therapeutics, Inc. (COYA)vs › | $116.00M | -0.05% | -43.47% | 9.13% | -18.50% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.56M | N/A | 143.89% | 2.05% | -53.47% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $125.77M | -71.83% | -71.89% | -76.88% | -67.88% |
| Entera Bio Ltd. (ENTX)vs › | $125.94M | -234.42% | -102.69% | -100.55% | -100.92% |
ROE
-30.1%
ROA
-26.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -30.12% |
| 2026-03-31 | -29.19% |
| 2025-12-31 | -28.38% |
| 2025-09-30 | -29.19% |
| 2025-06-30 | -28.60% |
| 2025-03-31 | -27.61% |
| 2024-12-31 | -26.44% |
| 2024-09-30 | -23.98% |
| 2024-06-30 | -22.60% |
| 2024-03-31 | -21.64% |
| 2023-12-31 | -21.74% |
| 2023-09-30 | -22.43% |
| 2023-06-30 | -22.46% |
| 2023-03-31 | -21.54% |
| 2022-12-31 | -20.80% |
| 2022-09-30 | -19.70% |
| 2022-06-30 | -17.92% |
| 2022-03-31 | -16.11% |
| 2021-12-31 | -14.15% |
| 2021-09-30 | -12.49% |
| 2021-06-30 | -10.31% |
| 2021-03-31 | -8.16% |
| 2020-12-31 | -7.59% |
| 2020-09-30 | -19.90% |
